Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk

Purpose: To investigate maximum tolerated dose (MTD), activity and predictive biomarkers of olaparib with carboplatin in BRCA wild-type (BRCAwt) high grade serous ovarian carcinoma (HGSOC) patients. Methods: A 3+3 dose escalation study examined olaparib capsules (400 mg twice daily [BID], days 1–7)...

Descripción completa

Detalles Bibliográficos
Autores principales: Lampert, Erika J., Hays, John L., Kohn, Elise C., Annunziata, Christina M., Minasian, Lori, Yu, Minshu, Gordon, Nicolas, Sissung, Tristan M., Chiou, Victoria L., Figg, William D., Houston, Nicole, Lee, Jung-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499601/
https://www.ncbi.nlm.nih.gov/pubmed/31080557
http://dx.doi.org/10.18632/oncotarget.26869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499601/
https://www.ncbi.nlm.nih.gov/pubmed/31080557
http://dx.doi.org/10.18632/oncotarget.26869

Ejemplares similares